2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.
Journal
Arthritis care & research
ISSN: 2151-4658
Titre abrégé: Arthritis Care Res (Hoboken)
Pays: United States
ID NLM: 101518086
Informations de publication
Date de publication:
08 Jul 2024
08 Jul 2024
Historique:
revised:
18
01
2024
received:
21
08
2023
accepted:
09
04
2024
medline:
8
7
2024
pubmed:
8
7
2024
entrez:
8
7
2024
Statut:
aheadofprint
Résumé
We provide evidence-based recommendations regarding screening for interstitial lung disease (ILD) and the monitoring for ILD progression in people with systemic autoimmune rheumatic diseases (SARDs), specifically rheumatoid arthritis, systemic sclerosis, idiopathic inflammatory myopathies, mixed connective tissue disease, and Sjögren disease. We developed clinically relevant population, intervention, comparator, and outcomes questions related to screening and monitoring for ILD in patients with SARDs. A systematic literature review was performed, and the available evidence was rated using the Grading of Recommendations, Assessment, Development, and Evaluation methodology. A Voting Panel of interdisciplinary clinician experts and patients achieved consensus on the direction and strength of each recommendation. Fifteen recommendations were developed. For screening people with these SARDs at risk for ILD, we conditionally recommend pulmonary function tests (PFTs) and high-resolution computed tomography of the chest (HRCT chest); conditionally recommend against screening with 6-minute walk test distance (6MWD), chest radiography, ambulatory desaturation testing, or bronchoscopy; and strongly recommend against screening with surgical lung biopsy. We conditionally recommend monitoring ILD with PFTs, HRCT chest, and ambulatory desaturation testing and conditionally recommend against monitoring with 6MWD, chest radiography, or bronchoscopy. We provide guidance on ILD risk factors and suggestions on frequency of testing to evaluate for the development of ILD in people with SARDs. This clinical practice guideline presents the first recommendations endorsed by the American College of Rheumatology and American College of Chest Physicians for the screening and monitoring of ILD in people with SARDs.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : American College of Rheumatology
Informations de copyright
© 2024 American College of Rheumatology.
Références
Fischer A, du Bois R. Interstitial lung disease in connective tissue disorders. Lancet 2012;380(9842):689–698.
Fischer A, Strek ME, Cottin V, et al. Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease‐Associated Interstitial Lung Disease Summit: a multidisciplinary approach to address challenges and opportunities. Arthritis Rheumatol 2019;71(2):182–195.
Flament T, Bigot A, Chaigne B, et al. Pulmonary manifestations of Sjögren's syndrome. Eur Respir Rev 2016;25(140):110–123.
Jeganathan N, Sathananthan M. Connective tissue disease‐related interstitial lung disease: prevalence, patterns, predictors, prognosis, and treatment. Lung 2020;198(5):735–759.
Steen VD, Conte C, Owens GR, et al. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994;37(9):1283–1289.
Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972‐2002. Ann Rheum Dis 2007;66(7):940–944.
Suliman YA, Dobrota R, Huscher D, et al. Brief report: pulmonary function tests: high rate of false‐negative results in the early detection and screening of scleroderma‐related interstitial lung disease. Arthritis Rheumatol 2015;67(12):3256–3261.
Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010;69(10):1809–1815.
England BR, Sayles H, Michaud K, et al. Cause‐specific mortality in male US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2016;68(1):36–45.
Olson AL, Swigris JJ, Sprunger DB, et al. Rheumatoid arthritis‐interstitial lung disease‐associated mortality. Am J Respir Crit Care Med 2011;183(3):372–378.
Sparks JA, Chang SC, Liao KP, et al. Rheumatoid arthritis and mortality among women during 36 years of prospective follow‐up: results from the Nurses’ Health Study. Arthritis Care Res (Hoboken) 2016;68(6):753–762.
Yoshida K, Lin TC, Wei MY, et al. Roles of postdiagnosis accumulation of morbidities and lifestyle changes in excess total and cause‐specific mortality risk in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2021;73(2):188–198.
Briggs DC, Vaughan RW, Welsh KI, et al. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet 1991;338(8768):661–662.
Silver RM, Bogatkevich G, Tourkina E, et al. Racial differences between blacks and whites with systemic sclerosis. Curr Opin Rheumatol 2012;24(6):642–648.
Steen V, Domsic RT, Lucas M, et al. A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. Arthritis Rheum 2012;64(9):2986–2994.
Khanna D, Tashkin DP, Denton CP, et al. Risk factors, and biomarkers in systemic sclerosis with interstitial lung disease. Am J Respir Crit Care Med 2020;201(6):650–660.
Giles JT, Danoff SK, Sokolove J, et al. Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease. Ann Rheum Dis 2014;73(8):1487–1494.
Mori S, Koga Y, Sugimoto M. Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respir Med 2012;106(11):1591–1599.
Natalini JG, Baker JF, Singh N, et al. Autoantibody seropositivity and risk for interstitial lung disease in a prospective male‐predominant rheumatoid arthritis cohort of U.S. veterans. Ann Am Thorac Soc 2021;18(4):598–605.
Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Int Med 2008;168(2):159–166.
Saag KG, Kolluri S, Koehnke RK, et al. Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities. Arthritis Rheum 1996;39(10):1711–1719.
Bongartz T, Nannini C, Medina‐Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population‐based study. Arthritis Rheum 2010;62(6):1583–1591.
Kim H, Cho SK, Song YJ, et al. Clinical characteristics of rheumatoid arthritis patients with interstitial lung disease: baseline data of a single‐center prospective cohort. Arthritis Res Ther 2023;25(1):43.
Hallowell RW, Paik JJ. Myositis‐associated interstitial lung disease: a comprehensive approach to diagnosis and management. Clin Exp Rheumatol 2022;40(2):373–383.
Wang Y, Hou Z, Qiu M, et al. Risk factors for primary Sjögren syndrome‐associated interstitial lung disease. J Thorac Dis 2018;10(4):2108–2117.
Luppi F, Sebastiani M, Silva M, et al. Interstitial lung disease in Sjögren's syndrome: a clinical review. Clin Exp Rheumatol 2020;38 Suppl 126(4):291–300.
Raghu G, Remy‐Jardin M, Myers JL, et al; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2018;198(5):e44–e68.
Andrews JC, Schünemann HJ, Oxman AD, et al. GRADE guidelines: 15. Going from evidence to recommendation‐determinants of a recommendation's direction and strength. J Clin Epidemiol. 2013;66(7):726–735.
Guyatt GH, Oxman AD, Vist GE, et al; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924–926.
Johnson SR, Turner AS, Goodman SM. How the American College of Rheumatology develops guidelines. Rheum Dis Clin North Am 2022;48(3):579–588.
Goh NS, Hoyles RK, Denton CP, et al. Short‐term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol 2017;69(8):1670–1678.
Hoffmann‐Vold AM, Aaløkken TM, Lund MB, et al. Predictive value of serial high‐resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis. Arthritis Rheumatol 2015;67(8):2205–2212.
Moore OA, Proudman SM, Goh N, et al. Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis‐related interstitial lung disease. Clin Exp Rheumatol 2015;33(4 Suppl 91):S111–S116.
Lima JP, Mirza RD, Guyatt GH. How to recognize a trustworthy clinical practice guideline. J Anesth Analg Crit Care 2023;3(1):9.
Guyatt GH, Oxman AD, Santesso N, et al. GRADE guidelines: 12. Preparing summary of findings tables‐binary outcomes. J Clin Epidemiol 2013;66(2):158–172.
Mirza RD, Bolster MB, Johnson SR, et al. Assessing patient values and preferences to inform the American College of Rheumatology/American College of Chest Physicians interstitial lung disease guidelines. Arthritis Care Res (Hoboken) 2024.
Johnson SR, Berstein EJ, Bolster MB, et al. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases. Arthritis Rheumatol 2024.
Manfredi A, Cassone G, Cerri S, et al; GISEA (Gruppo Italiano Studio Early Arthritis). Diagnostic accuracy of a velcro sound detector (VECTOR) for interstitial lung disease in rheumatoid arthritis patients: the InSPIRAtE validation study (INterStitial pneumonia in rheumatoid ArThritis with an electronic device). BMC Pulm Med 2019;19(1):111.
Hax V, Bredemeier M, Didonet Moro AL, et al. Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis. Semin Arthritis Rheum 2017;47(2):228–234.
Nguyen ET, Hague C, Manos D, et al. Canadian Society of Thoracic Radiology/Canadian Association of Radiologists best practice guidance for investigation of acute pulmonary embolism, part 2: technical issues and interpretation pitfalls. Can Assoc Radiol J 2022;73(1):214–227.
Chen YH, Velayudhan V, Weltman DI, et al. Waiting to exhale: salvaging the nondiagnostic CT pulmonary angiogram by using expiratory imaging to improve contrast dynamics. Emerg Radiol 2008;15(3):161–169.
Mortimer AM, Singh RK, Hughes J, et al. Use of expiratory CT pulmonary angiography to reduce inspiration and breath‐hold associated artefact: contrast dynamics and implications for scan protocol. Clin Radiol 2011;66(12):1159–1166.
Bernstein EJ, Jaafar S, Assassi S, et al. Performance characteristics of pulmonary function tests for the detection of interstitial lung disease in adults with early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol 2020;72(11):1892–1896.
Hoffmann T, Oelzner P, Franz M, et al. Assessing the diagnostic value of a potential screening tool for detecting early interstitial lung disease at the onset of inflammatory rheumatic diseases. Arthritis Res Ther 2022;24(1):107.
Showalter K, Hoffmann A, Rouleau G, et al. Performance of forced vital capacity and lung diffusion cutpoints for associated radiographic interstitial lung disease in systemic sclerosis. J Rheumatol 2018;45(11):1572–1576.
Picano E, Matucci‐Cerinic M. Unnecessary radiation exposure from medical imaging in the rheumatology patient. Rheumatology (Oxford) 2011;50(9):1537–1539.
The 2007 recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP 2007;37(2–4):1–332.
Hall EJ, Brenner DJ. Cancer risks from diagnostic radiology. Br J Radiol 2008;81(965):362–378.
Takahashi H, Kuroki Y, Tanaka H, et al. Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis. Am J Respir Crit Care Med 2000;162(1):258–263.
Clements PJ, Goldin JG, Kleerup EC, et al. Regional differences in bronchoalveolar lavage and thoracic high‐resolution computed tomography results in dyspneic patients with systemic sclerosis. Arthritis Rheum 2004;50(6):1909–1917.
Silver RM, Miller KS, Kinsella MB, et al. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 1990;88(5):470–476.
Tomassetti S, Ravaglia C, Puglisi S, et al. Impact of lung biopsy information on treatment strategy of patients with interstitial lung diseases. Ann Am Thorac Soc 2022;19(5):737–745.
Bernstein EJ, Khanna D, Lederer DJ. Screening high‐resolution computed tomography of the chest to detect interstitial lung disease in systemic sclerosis: a global survey of rheumatologists. Arthritis Rheumatol 2018;70(6):971–972.
Carnevale A, Silva M, Maietti E, et al. Longitudinal change during follow‐up of systemic sclerosis: correlation between high‐resolution computed tomography and pulmonary function tests. Clin Rheumatol 2021;40(1):213–219.
Kim GHJ, Tashkin DP, Lo P, et al. Using transitional changes on high‐resolution computed tomography to monitor the impact of cyclophosphamide or mycophenolate mofetil on systemic sclerosis‐related interstitial lung disease. Arthritis Rheumatol 2020;72(2):316–325.
Kim HJ, Brown MS, Elashoff R, et al. Quantitative texture‐based assessment of one‐year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide. Eur Radiol 2011;21(12):2455–2465.
Roca F, Dominique S, Schmidt J, et al. Interstitial lung disease in primary Sjögren's syndrome. Autoimmun Rev 2017;16(1):48–54.
Tardella M, Di Carlo M, Carotti M, et al. A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis‐interstitial lung disease. Inflammopharmacology 2022;30(3):705–712.
Naccache JM, Gibiot Q, Monnet I, et al. Lung cancer and interstitial lung disease: a literature review. J Thorac Dis 2018;10(6):3829–3844.
Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Criti Care Med 2008;177(11):1248–1254.
Goldin JG, Lynch DA, Strollo DC, et al; Scleroderma Lung Study Research Group. High‐resolution CT scan findings in patients with symptomatic scleroderma‐related interstitial lung disease. Chest 2008;134(2):358–367.
Khanna D, Tseng CH, Farmani N, et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum 2011;63(10):3078–3085.
Lee JS, Kim GJ, Ha YJ, et al. The extent and diverse trajectories of longitudinal changes in rheumatoid arthritis interstitial lung diseases using quantitative HRCT scores. J Clin Med 2021;10(17):3812.
Moore OA, Goh N, Corte T, et al. Extent of disease on high‐resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis‐related interstitial lung disease. Rheumatology (Oxford) 2013;52(1):155–160.
Occhipinti M, Bosello S, Sisti LG, et al. Quantitative and semi‐quantitative computed tomography analysis of interstitial lung disease associated with systemic sclerosis: a longitudinal evaluation of pulmonary parenchyma and vessels. PLoS One 2019;14(3):e0213444.
Shao G, Hawle P, Akbari K, et al. Clinical, imaging, and blood biomarkers to assess 1‐year progression risk in fibrotic interstitial lung diseases‐development and validation of the honeycombing, traction bronchiectasis, and monocyte (HTM)‐score. Front Med (Lausanne) 2022;9:1043720.
Tanizawa K, Handa T, Nakashima R, et al. The prognostic value of HRCT in myositis‐associated interstitial lung disease. Respir Med 2013;107(5):745–752.
Tashkin DP, Volkmann ER, Tseng CH, et al. Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. Ann Rheum Dis 2016;75(2):374–381.
Wada DT, de Almeida FA, de Moraes DA, et al. Automatic quantitative computed tomography evaluation of the lungs in patients with systemic sclerosis treated with autologous stem cell transplantation. J Clin Rheumatol 2020;26(7S Suppl 2):S158–S164.
Waseda Y, Johkoh T, Prosch H, et al. Chest computed tomography findings of adult patients with antimelanoma differentiation‐associated protein 5 antibody‐positive interstitial lung disease. Mod Rheumatol 2022;32(2):365–372.